Glen Raffel

883 total citations
36 papers, 505 citations indexed

About

Glen Raffel is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Glen Raffel has authored 36 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 15 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Glen Raffel's work include Acute Myeloid Leukemia Research (17 papers), Hematopoietic Stem Cell Transplantation (10 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Glen Raffel is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Hematopoietic Stem Cell Transplantation (10 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Glen Raffel collaborates with scholars based in United States, Canada and France. Glen Raffel's co-authors include Dana E. Cullen, Jonathan L. Jesneck, Kalindi Parmar, Naomi Rosenberg, Olivier Bernard, Thomas Mercher, Hirokazu Shigematsu, Koichi Akashi, Ifor R. Williams and D. Gary Gilliland and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Glen Raffel

33 papers receiving 494 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Glen Raffel United States	11	337	162	71	66	65	36	505
Soumen Chakraborty India	13	434 1.3×	197 1.2×	50 0.7×	60 0.9×	80 1.2×	27	635
Yakun Pang China	11	253 0.8×	173 1.1×	90 1.3×	50 0.8×	49 0.8×	22	458
Paul W. Hollenbach United States	11	453 1.3×	200 1.2×	57 0.8×	49 0.7×	92 1.4×	13	664
Meropi Athanasiou United States	12	450 1.3×	100 0.6×	80 1.1×	56 0.8×	120 1.8×	15	639
Sean F. Landrette United States	12	441 1.3×	191 1.2×	61 0.9×	62 0.9×	108 1.7×	18	663
Ashwini Yenamandra United States	9	363 1.1×	100 0.6×	65 0.9×	46 0.7×	107 1.6×	21	523
Daniel P. Sejas United States	10	475 1.4×	146 0.9×	130 1.8×	48 0.7×	124 1.9×	10	641
Yuxia Zhan United States	12	202 0.6×	151 0.9×	55 0.8×	70 1.1×	77 1.2×	20	425
Peter Haviernik United States	13	297 0.9×	89 0.5×	79 1.1×	31 0.5×	88 1.4×	25	441
Abilasha Rao‐Bhatia Canada	6	302 0.9×	222 1.4×	97 1.4×	37 0.6×	157 2.4×	6	509

Countries citing papers authored by Glen Raffel

Since Specialization

Citations

This map shows the geographic impact of Glen Raffel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glen Raffel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glen Raffel more than expected).

Fields of papers citing papers by Glen Raffel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glen Raffel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glen Raffel. The network helps show where Glen Raffel may publish in the future.

Co-authorship network of co-authors of Glen Raffel

This figure shows the co-authorship network connecting the top 25 collaborators of Glen Raffel. A scholar is included among the top collaborators of Glen Raffel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Glen Raffel. Glen Raffel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DiPersio, John F., Guenther Koehne, Nirali N. Shah, et al.. (2024). A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML). Blood. 144(Supplement 1). 2873–2873.

Koehne, Guenther, Benjamin Tomlinson, Hyung C. Suh, et al.. (2023). P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS. HemaSphere. 7(S3). e24418bc–e24418bc. 3 indexed citations

DiPersio, John F., Steven M. Devine, Jonathan Hoggatt, et al.. (2020). Phase 1 Clinical Study of Mgta-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs without G-CSF. Biology of Blood and Marrow Transplantation. 26(3). S55–S55. 1 indexed citations

Orchard, Paul J., Glen Raffel, Ryan Shanley, et al.. (2020). Mgta-456 Cell Therapy in Inherited Metabolic Disease (IMD) Yields Rapid and Durable Long-Term Improvement of Disease-Specific Outcomes in a Phase 2 Trial. Biology of Blood and Marrow Transplantation. 26(3). S19–S19. 2 indexed citations

Stefanski, Heather E., Claudio G. Brunstein, David H. McKenna, et al.. (2019). Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD). Blood. 134(Supplement_1). 804–804. 4 indexed citations

Orchard, Paul J., Glen Raffel, Carolyn H. Condon, et al.. (2018). Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34+ Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD). Blood. 132(Supplement 1). 3467–3467. 1 indexed citations

Saini, Neeraj, et al.. (2017). Targeting the Mechanism of c-Mpl Exon-Inclusion through Antisense Oligonucleotides Yields a Dominant Negative Isoform. Blood. 130. 383–383. 1 indexed citations

Černý, Jan, et al.. (2017). Outcomes of Second Allogeneic Stem Cell Transplantation: Single Center Analysis. Biology of Blood and Marrow Transplantation. 23(3). S264–S264. 1 indexed citations

Dibas, Adnan, et al.. (2016). CD44 induced enhancement of phosphatase activity and calcium influx: Modifications of EGR-1 expression and cell proliferation. Biochemistry and Biophysics Reports. 6. 172–178. 8 indexed citations

10.

Cantor, Sharon B., et al.. (2016). Impairment of fetal hematopoietic stem cell function in the absence of Fancd2. Experimental Hematology. 48. 79–86. 9 indexed citations

11.

Xiao, Nan, et al.. (2014). Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl. Blood. 125(6). 941–948. 36 indexed citations

12.

Tam, Winnie F., Patricia S. Hähnel, Andrea Schüler, et al.. (2012). STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2. Cancer Research. 73(1). 373–384. 26 indexed citations

13.

Xiao, Nan, Kelly Morgan, Rachel Okabe, et al.. (2012). Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress. Blood. 119(21). 4898–4907. 33 indexed citations

14.

Xiao, Nan, et al.. (2011). Ott1(Rbm15)-Deficient Hematopoietic Stem Cells Are Unable to Maintain Quiescence During Replicative Stress and Display Features of Premature Aging,. Blood. 118(21). 3433–3433. 1 indexed citations

15.

Ramanathan, Muthalagu, Zheng Zhou, Jan Černý, et al.. (2010). High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML). Blood. 116(21). 3290–3290. 1 indexed citations

16.

Mercher, Thomas, Glen Raffel, Sandra Moore, et al.. (2009). The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. Journal of Clinical Investigation. 119(4). 852–64. 73 indexed citations

17.

Raffel, Glen, et al.. (2001). Diagnostic Dilemmas in Oncology. Journal of Clinical Oncology. 19(23). 4341–4343. 9 indexed citations

18.

Moy, Beverly, et al.. (2000). Hemolytic Uremic Syndrome Associated With Clopidogrel. Archives of Internal Medicine. 160(9). 1370–1370. 18 indexed citations

19.

Raffel, Glen, Kalindi Parmar, & Naomi Rosenberg. (1996). In Vivo Association of v-Abl with Shc Mediated by a Non-phosphotyrosine-dependent SH2 Interaction. Journal of Biological Chemistry. 271(9). 4640–4645. 56 indexed citations

20.

Overbeck, W. & Glen Raffel. (1970). [Results of surgery for rectal neoplasms].. PubMed. 218(4). 338–45. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact